Daruka Mahadevan Selected Research

MLN 8237

12/2018	Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.
11/2018	Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC/BCL2-addicted diffuse large B-cell lymphoma.
11/2017	Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy.
10/2017	Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas.
9/2015	Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.
7/2015	Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.
1/2014	Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
4/2012	Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.
4/2011	Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daruka Mahadevan Research Topics

Disease

55	Neoplasms (Cancer) 01/2022 - 01/2003
11	Lymphoma (Lymphomas) 11/2018 - 12/2005
10	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2020 - 05/2011
7	Adenocarcinoma 01/2022 - 12/2006
7	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 06/2009
5	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 12/2006
5	Prostatic Neoplasms (Prostate Cancer) 01/2020 - 09/2007
5	Pancreatic Neoplasms (Pancreatic Cancer) 07/2019 - 01/2003
5	Carcinogenesis 12/2018 - 03/2003
5	Glioblastoma (Glioblastoma Multiforme) 01/2018 - 01/2008
4	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2022 - 12/2005
4	Multiple Myeloma 01/2022 - 03/2013
4	B-Cell Lymphoma (Lymphoma, B Cell) 12/2018 - 06/2012
4	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 11/2017 - 12/2005
3	Breast Neoplasms (Breast Cancer) 10/2019 - 01/2004
3	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 01/2003
3	Aneuploidy (Aneuploid) 11/2018 - 01/2014
3	T-Cell Lymphoma (Lymphoma, T Cell) 09/2015 - 01/2013
3	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 06/2012 - 04/2011
2	Neurofibrosarcoma (MPNST) 01/2022 - 09/2019
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020 - 11/2018
2	Carcinoma (Carcinomatosis) 01/2020 - 06/2009
2	Genomic Instability 01/2019 - 01/2016
2	Neutropenia 12/2018 - 02/2005
2	Polyploidy 11/2018 - 04/2011
2	Disease Progression 01/2018 - 07/2006
2	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2018 - 07/2016
2	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 02/2015 - 01/2015
2	Leukemia 04/2010 - 10/2004
2	Nervous System Diseases (Neurological Disorders) 09/2007 - 01/2006
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2006 - 02/2005
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2006 - 10/2004
1	Neurofibromatosis 1 (Neurofibromatosis Type I) 01/2022
1	Schwannomatosis 01/2022
1	Acoustic Neuroma (Acoustic Neurinoma) 01/2022
1	Neurofibromatoses (Neurofibromatosis) 01/2022
1	Neoplasm Metastasis (Metastasis) 01/2022
1	Melanoma (Melanoma, Malignant) 01/2022
1	Plexiform Neurofibroma 01/2022

Drug/Important Bio-Agent (IBA)

9	Pharmaceutical PreparationsIBA 01/2022 - 03/2003
9	MLN 8237IBA 12/2018 - 04/2011
8	Aurora KinasesIBA 12/2018 - 01/2003
7	Phosphotransferases (Kinase)IBA 09/2017 - 01/2003
6	Biomarkers (Surrogate Marker)IBA 03/2020 - 11/2009
6	Monoclonal AntibodiesIBA 01/2017 - 12/2006
5	Immune Checkpoint InhibitorsIBA 01/2022 - 07/2016
5	Rituximab (Mabthera)FDA Link 12/2018 - 04/2012
4	Aurora Kinase AIBA 12/2018 - 01/2014
4	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 02/2015 - 05/2009
4	Gemcitabine FDA Link 06/2013 - 03/2009
3	Bevacizumab (Avastin)FDA Link 01/2022 - 10/2017
3	Vincristine (Oncovin)FDA LinkGeneric 12/2018 - 04/2012
3	Etoposide (VP 16)FDA LinkGeneric 12/2018 - 01/2013
3	Cisplatin (Platino)FDA LinkGeneric 12/2018 - 01/2013
3	Docetaxel (Taxotere)FDA Link 06/2012 - 04/2011
3	Proteins (Proteins, Gene)FDA Link 04/2012 - 09/2004
3	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 09/2008 - 01/2003
2	Epirubicin (Ellence)FDA LinkGeneric 01/2022 - 12/2009
2	AntimetabolitesIBA 01/2022 - 09/2017
2	pembrolizumabIBA 01/2022 - 01/2022
2	LigandsIBA 12/2020 - 12/2006
2	Circulating Tumor DNAIBA 03/2020 - 01/2019
2	RNA (Ribonucleic Acid)IBA 12/2019 - 10/2019
2	Cell Adhesion MoleculesIBA 12/2019 - 02/2015
2	Carcinoembryonic AntigenIBA 12/2019 - 02/2015
2	Protein Kinases (Protein Kinase)IBA 12/2018 - 04/2003
2	PlatinumIBA 12/2018 - 09/2017
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 11/2018 - 04/2010
2	ublituximabIBA 04/2018 - 01/2017
2	Temozolomide (Temodar)FDA LinkGeneric 01/2018 - 10/2017
2	Bortezomib (Velcade)FDA Link 01/2018 - 04/2013
2	Methylprednisolone FDA LinkGeneric 01/2018 - 01/2013
2	(2,4- dihydroxy- 5- isopropylphenyl)- (5- (4- methylpiperazin- 1- ylmethyl)- 1,3- dihydroisoindol- 2- yl)methanoneIBA 01/2016 - 01/2015
2	Imatinib Mesylate (Gleevec)FDA Link 02/2015 - 01/2015
2	Lenalidomide (CC 5013)FDA Link 03/2012 - 02/2005
2	Peptides (Polypeptides)IBA 09/2011 - 01/2008
2	amuvatinibIBA 12/2009 - 05/2009
2	Biological ProductsIBA 11/2009 - 12/2005
2	CytokinesIBA 06/2009 - 10/2006
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 05/2009 - 03/2009
2	Phosphatidylinositols (Phosphatidylinositol)IBA 09/2008 - 09/2004
1	dinaciclibIBA 01/2022
1	Toll-Like Receptor 9IBA 01/2022
1	NucleosidesIBA 01/2022
1	Uridine KinaseIBA 01/2022
1	Ifosfamide FDA LinkGeneric 01/2022
1	130-nm albumin-bound paclitaxelIBA 01/2022
1	AZD 6244IBA 01/2022
1	tilsotolimodIBA 01/2022
1	fluorocyclopentenylcytosineIBA 01/2022
1	Drug CombinationsIBA 02/2021
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2021

Therapy/Procedure

36	Therapeutics 01/2022 - 10/2004
8	Drug Therapy (Chemotherapy) 07/2019 - 09/2005
4	Immunotherapy 01/2022 - 11/2018
4	Radiotherapy 01/2021 - 12/2009
2	Aftercare (After-Treatment) 01/2022 - 11/2018
2	Castration 12/2018 - 12/2015
1	Off-Label Use 01/2022
1	Immunomodulation 01/2022